# US 2026/0083764 A1 · Beta-1,3'-galactosyllactose for the treatment of gut barrier function diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083764 A1
- Document ID: US20260083764A1
- Status: Published application
- Kind: A1
- Application number: 19/398,141
- Filed: 2025-11-24
- Published: 2026-03-26
- Earliest claimed: 2019-05-15
- Assignees: N.V. Nutricia
- Applicants: N.V. Nutricia
- Inventors: Saskia Braber; Belinda Potappel - van 't Land; Selma Paulien Wiertsema; Johan Garssen; Bernd Stahl; Marko Mank
- Web page: https://patentgrep.com/patent/US20260083764A1

## CPC

- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A23L 29/04: {Fatty acids or derivatives}
- A23L 29/30: containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin (products from apiculture A23L21/20; artificial sweetening agents A23L27/30)
- A23L 33/12: Fatty acids or derivatives thereof
- A23L 33/125: containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates (indigestible substances A23L33/21)
- A23L 33/17: Amino acids, peptides or proteins
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the use of beta1,3′-galactosyllactose for improving the gut barrier function. This can in particular be administered to subjects at risk for increased gut barrier permeability, preferably infants and young children.

## Claims

### Claim 1

Infant formula, follow on formula or young child formula, comprising:
a. 1.6 to 4 g protein based on 100 kcal,
b. 5 to 20 g digestible carbohydrates based on 100 kcal,
c. 3 to 7 g lipid based on 100 kcal, wherein the lipid comprises:
i. LC-PUFA selected from the group consisting of DHA, EPA and ARA, wherein the sum of DHA, ARA and EPA is at least 1 wt % based on total fatty acids, and
ii. at least 0.1 wt % EPA based on total fatty acids and at least 0.5 wt % DHA based on total fatty acids, and at least 0.25 wt % ARA based on total fatty acids,
d. 0.25 to 2.5 g galacto-oligosaccharides per 100 ml of ready to drink formula, wherein the galacto-oligosaccharides comprise Gal (beta 1-3)-Gal (beta 1-4)-Glc in an amount of 10 to 50 mg per 100 ml ready to drink formula
wherein the infant formula, follow on formula or young child formula is not human milk.

### Claim 2 (depends on 1)

The infant formula, follow on formula or young child formula according to claim 1, wherein the protein comprises bovine whey proteins and/or bovine casein.

### Claim 3 (depends on 1)

The infant formula, follow on formula or young child formula according to claim 1, wherein the lipid comprises a combination of vegetable lipids and at least one oil selected from the group consisting of fish oil, algae oil, fungal oil, and bacterial oil.

### Claim 4 (depends on 1)

The infant formula, follow on formula or young child formula according to claim 1, wherein the infant formula, follow on formula or young child formula is in the form of a powder, suitable to reconstitute with water to provide a ready to drink infant formula, follow on formula or young child formula.

### Claim 5 (depends on 1)

A method for increasing the intestinal barrier function and/or for prevention and/or treatment of intestinal barrier disruption in infants or young children that suffer from food allergy and/or atopic dermatitis, the method comprising administering an infant formula, follow on formula or young child formula according to claim 1 to the infants or young children.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the infant formula, follow on formula or young child formula is administered to infants or young children of 0 to 36 month of age.

### Claim 7 (depends on 5)

The method according to claim 5, wherein the infant formula, follow on formula or young child formula comprises 0.07 to 3.75 wt % Gal (beta 1-3)-Gal (beta 1-4)-Glc, based on dry weight of the nutritional composition, and/or wherein the daily dose administered is 0.10 to 6 g Gal (beta 1-3)-Gal (beta 1-4)-Glc.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the infant formula, follow on formula or young child formula comprises 0.35 to 3.7 g galacto-oligosaccharides per 100 kcal of the formula.

### Claim 9 (depends on 1)

A method for the treatment, prevention and/or alleviation of a toxin exposure associated condition in infants or young children that suffer from food allergy and/or atopic dermatitis, the method comprising administering an infant formula, follow on formula or young child formula according to claim 1 to the infants or young children that suffer from food allergy and/or atopic dermatitis, wherein the toxin exposure associated condition is a toxin mediated intestinal barrier disruption.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the infant formula, follow on formula or young child formula is administered to infants or young children of 0 to 36 month of age.

### Claim 11 (depends on 9)

The method according claim 9, wherein the infant formula, follow on formula or young child formula comprises 0.07 to 3.75 wt % Gal (beta 1-3)-Gal (beta 1-4)-Glc, based on dry weight of the nutritional composition, and/or wherein the daily dose administered is 0.10 to 6 g Gal (beta 1-3)-Gal (beta 1-4)-Glc.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the infant formula, follow on formula or young child formula comprises 0.35 to 3.7 g galacto-oligosaccharides per 100 kcal of the formula.
